Genetic polymorphisms in host response to meningococcal infection: The role of susceptibility and severity genes

Vaccine

Volumn 27, Issue SUPPL. 2, 2009, Pages

  Wright, Victoria ^a   Hibberd, Martin ^b   Levin, Michael ^a  

^a Wright Fleming Institute   (United Kingdom)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

Genetic susceptibility; Meningococcal; Severity

Indexed keywords

DISEASE SEVERITY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; INFECTION SENSITIVITY; MENINGOCOCCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

DISEASE SUSCEPTIBILITY; HUMANS; MENINGOCOCCAL INFECTIONS; POLYMORPHISM, GENETIC;

EID: 67349254110     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.002     Document Type: Review

References (123)

1. Sorensen T.I., Nielsen G.G., Andersen P.K., and Teasdale T.W. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 318 12 (1988) 727-732
2. WTCCC. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 7145 (2007) 661-678
3. Haralambous E., Weiss H.A., Radalowicz A., Hibberd M.L., Booy R., and Levin M. Sibling familial risk ratio of meningococcal disease in UK Caucasians. Epidemiol Infect 130 3 (2003) 413-418
4. Ioannidis J.P. Why most published research findings are false. PLoS Med 2 8 (2005) e124
5. Blackwell C.C., Weir D.M., James V.S., Todd W.T., Banatvala N., Chaudhuri A.K., et al. Secretor status, smoking and carriage of Neisseria meningitidis. Epidemiol Infect 104 2 (1990) 203-209
6. Blackwell C.C., Jonsdottir K., Hanson M., Todd W.T., Chaudhuri A.K., Mathew B., et al. Non-secretion of ABO antigens predisposing to infection by Neisseria meningitidis and Streptococcus pneumoniae. Lancet 2 8501 (1986) 284-285
7. Kornstad L., Heistoo A.L., Michaelsen T.E., and Bjune G. ABH secretor status, as judged by the Lewis phenotypes, in Norwegian survivors from meningococcal disease. APMIS 101 10 (1993) 791-794
8. Callaghan M.J., Rockett K., Banner C., Haralambous E., Betts H., Faust S., et al. Haplotypic diversity in human CEACAM genes: effects on susceptibility to meningococcal disease. Genes Immun 9 1 (2008) 30-37
9. Goldschneider I., Gotschlich E.C., and Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129 6 (1969) 1307-1326
10. Goldschneider I., Gotschlich E.C., and Artenstein M.S. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 129 6 (1969) 1327-1348
11. Edwards E.A., Devine L.F., Sengbusch G.H., and Ward H.W. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand J Infect Dis 9 2 (1977) 105-110
12. Marks M.I., Frasch C.E., and Shapera R.M. Meningococcal colonization and infection in children and their household contacts. Am J Epidemiol 109 5 (1979) 563-571
13. Fearon D.T. Seeking wisdom in innate immunity. Nature 388 6640 (1997) 323-324
14. Fearon D.T., and Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science 272 5258 (1996) 50-53
15. Medzhitov R., and Janeway Jr. C.A. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91 3 (1997) 295-298
16. Heppner G., and Weiss D.W. High susceptibility of Strain A mice to endotoxin and endotoxin-red blood cell mixtures. J Bacteriol 90 3 (1965) 696-703
17. Watson J., Kelly K., Largen M., and Taylor B.A. The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J Immunol 120 2 (1978) 422-424
18. Watson J., Riblet R., and Taylor B.A. The response of recombinant inbred strains of mice to bacterial lipopolysaccharides. J Immunol 118 6 (1977) 2088-2093
19. Woods J.P., Frelinger J.A., Warrack G., and Cannon J.G. Mouse genetic locus Lps influences susceptibility to Neisseria meningitidis infection. Infect Immun 56 8 (1988) 1950-1955
20. DeVoe I.W. The meningococcus and mechanisms of pathogenicity. Microbiol Rev 46 2 (1982) 162-190
21. Smirnova I., Mann N., Dols A., Derkx H.H., Hibberd M.L., Levin M., et al. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci USA 100 10 (2003) 6075-6080
22. Faber J., Meyer C.U., Gemmer C., Russo A., Finn A., Murdoch C., et al. Human toll-like receptor 4 mutations are associated with susceptibility to invasive meningococcal disease in infancy. Pediatr Infect Dis J 25 1 (2006) 80-81
23. Faber J., Henninger N., Finn A., Zenz W., Zepp F., and Knuf M. A toll-like receptor 4 variant is associated with fatal outcome in children with invasive meningococcal disease. Acta Paediatr 98 3 (2009) 548-552
24. Read R.C., Pullin J., Gregory S., Borrow R., Kaczmarski E.B., di Giovine F.S., et al. A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis 184 5 (2001) 640-642
25. Allen A., Obaro S., Bojang K., Awomoyi A.A., Greenwood B.M., Whittle H., et al. Variation in Toll-like receptor 4 and susceptibility to group A meningococcal meningitis in Gambian children. Pediatr Infect Dis J 22 11 (2003) 1018-1019
26. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25 2 (2000) 187-191
27. Massari P., Visintin A., Gunawardana J., Halmen K.A., King C.A., Golenbock D.T., et al. Meningococcal porin PorB binds to TLR2 and requires TLR1 for signaling. J Immunol 176 4 (2006) 2373-2380
28. Sjolinder H., Mogensen T.H., Kilian M., Jonsson A.B., and Paludan S.R. Important role for Toll-like receptor 9 in host defense against meningococcal sepsis. Infect Immun 76 11 (2008) 5421-5428
29. Beutler B. Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol 12 1 (2000) 20-26
30. Beutler B. Toll-like receptors: how they work and what they do. Curr Opin Hematol 9 1 (2002) 2-10
31. Qureshi S.T., Gros P., and Malo D. The Lps locus: genetic regulation of host responses to bacterial lipopolysaccharide. Inflamm Res 48 12 (1999) 613-620
32. Akira S. Toll-like receptors and innate immunity. Adv Immunol 78 1 (2001) 1-56
33. Medvedev A.E., Lentschat A., Kuhns D.B., Blanco J.C., Salkowski C., Zhang S., et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med 198 4 (2003) 521-531
34. Janeway C.A., Travers P., Walport M., and Shlomchik M. Immunobiology: the immune system in health and disease (2004), Garland Science, London
35. Emonts M., Hazelzet J.A., de Groot R., and Hermans P.W. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 3 9 (2003) 565-577
36. Figueroa J.E., and Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 4 3 (1991) 359-395
37. Densen P. Complement deficiencies and meningococcal disease. Clin Exp Immunol 86 Suppl. 1 (1991) 57-62
38. Ellison III R.T., Kohler P.F., Curd J.G., Judson F.N., and Reller L.B. Prevalence of congenital or acquired complement deficiency in patients with sporadic meningocococcal disease. N Engl J Med 308 16 (1983) 913-916
39. Fijen C.A., Kuijper E.J., Hannema A.J., Sjoholm A.G., and van Putten J.P. Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups. Lancet 2 8663 (1989) 585-588
40. Tebruegge M., and Curtis N. Epidemiology, etiology, pathogenesis, and diagnosis of recurrent bacterial meningitis. Clin Microbiol Rev 21 3 (2008) 519-537
41. Bols A., Janssens J., Peetermans W., Stevens E., and Bobbaers H. Recurrent meningococcal infections in a patient with congenital C5 deficiency. Acta Clin Belg 48 1 (1993) 42-47
42. Haeney M.R., Thompson R.A., Faulkner J., Mackintosh P., and Ball A.P. Recurrent bacterial meningitis in patients with genetic defects of terminal complement components. Clin Exp Immunol 40 1 (1980) 16-24
43. Rosen M.S., Lorber B., and Myers A.R. Chronic meningococcal meningitis. An association with C5 deficiency. Arch Intern Med 148 6 (1988) 1441-1442
44. Figueroa J., Andreoni J., and Densen P. Complement deficiency states and meningococcal disease. Immunol Res 12 3 (1993) 295-311
45. Fijen C.A., Kuijper E.J., te Bulte M.T., Daha M.R., and Dankert J. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis 28 1 (1999) 98-105
46. Hibberd M.L., Sumiya M., Summerfield J.A., Booy R., Levin M., and Meningococcal Research Group. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet 353 9158 (1999) 1049-1053
47. Salimans M.M., Bax W.A., Stegeman F., van Deuren M., Bartelink A.K., and van Dijk H. Association between familial deficiency of mannose-binding lectin and mutations in the corresponding gene and promoter region. Clin Diagn Lab Immunol 11 4 (2004) 806-807
48. Bax W.A., Cluysenaer O.J., Bartelink A.K., Aerts P.C., Ezekowitz R.A., and van Dijk H. Association of familial deficiency of mannose-binding lectin and meningococcal disease. Lancet 354 9184 (1999) 1094-1095
49. Faber J., Schuessler T., Finn A., Murdoch C., Zenz W., Habermehl P., et al. Age-dependent association of human mannose-binding lectin mutations with susceptibility to invasive meningococcal disease in childhood. Pediatr Infect Dis J 26 3 (2007) 243-246
50. Brouwer M.C., de Gans J., Heckenberg S.G., Zwinderman A.H., van der Poll T., and van de Beek D. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 9 1 (2009) 31-44
51. Summerfield J.A., Sumiya M., Levin M., and Turner M.W. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 314 7089 (1997) 1229-1232
52. Brandtzaeg P., and Cartwright K. Pathogenesis of meningococcal infections. In: Cartwright K. (Ed). Meningococcal disease (1995), John Wiley and Sons, London 115-146
53. Walport M.J. Complement. First of two parts. N Engl J Med 344 14 (2001) 1058-1066
54. Walport M.J. Complement. Second of two parts. N Engl J Med 344 15 (2001) 1140-1144
55. Lambris J.D., Ricklin D., and Geisbrecht B.V. Complement evasion by human pathogens. Nat Rev Microbiol 6 2 (2008) 132-142
56. Blom A.M., Villoutreix B.O., and Dahlback B. Complement inhibitor C4b-binding protein-friend or foe in the innate immune system?. Mol Immunol 40 18 (2004) 1333-1346
57. Fearon D.T., and Austen K.F. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med 142 4 (1975) 856-863
58. Sjoholm A.G., Braconier J.H., and Soderstrom C. Properdin deficiency in a family with fulminant meningococcal infections. Clin Exp Immunol 50 2 (1982) 291-297
59. Densen P., Weiler J.M., Griffiss J.M., and Hoffmann L.G. Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination. N Engl J Med 316 15 (1987) 922-926
60. Spath P.J., Sjoholm A.G., Fredrikson G.N., Misiano G., Scherz R., Schaad U.B., et al. Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n). Clin Exp Immunol 118 2 (1999) 278-284
61. Fijen C.A., Derkx B.H., Kuijper E.J., Mannens M., Poort S.R., Peters M., et al. Fulminant meningococcal septic shock in a boy with combined inherited properdin and protein C deficiency. Clin Exp Immunol 102 2 (1995) 290-296
62. Bathum L., Hansen H., Teisner B., Koch C., Garred P., Rasmussen K., et al. Association between combined properdin and mannose-binding lectin deficiency and infection with Neisseria meningitidis. Mol Immunol 43 5 (2006) 473-479
63. Biesma D.H., Hannema A.J., van Velzen-Blad H., Mulder L., van Zwieten R., Kluijt I., et al. A family with complement factor D deficiency. J Clin Invest 108 2 (2001) 233-240
64. Sprong T., Roos D., Weemaes C., Neeleman C., Geesing C.L., Mollnes T.E., et al. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood 107 12 (2006) 4865-4870
65. Haralambous E., Dolly S.O., Hibberd M.L., Litt D.J., Udalova I.A., O'Dwyer C., et al. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand J Infect Dis 38 9 (2006) 764-771
66. Fijen C.A., Kuijper E.J., Te Bulte M., van de Heuvel M.M., Holdrinet A.C., Sim R.B., et al. Heterozygous and homozygous factor H deficiency states in a Dutch family. Clin Exp Immunol 105 3 (1996) 511-516
67. Nielsen H.E., Christensen K.C., Koch C., Thomsen B.S., Heegaard N.H., and Tranum-Jensen J. Hereditary, complete deficiency of complement factor H associated with recurrent meningococcal disease. Scand J Immunol 30 6 (1989) 711-718
68. Schneider M.C., Prosser B.E., Caesar J.J., Kugelberg E., Li S., Zhang Q., et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458 7240 (2009) 890-893
69. McNeil L.K., Murphy E., Zhao X.J., Guttmann S., Harris S.L., Scott A.A., et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine (2009) [epub ahead of print February 5]
70. Jack D.L., Cole J., Naylor S.C., Borrow R., Kaczmarski E.B., Klein N.J., et al. Genetic polymorphism of the binding domain of surfactant protein-A2 increases susceptibility to meningococcal disease. Clin Infect Dis 43 11 (2006) 1426-1433
71. Sanders L.A., Feldman R.G., Voorhorst-Ogink M.M., de Haas M., Rijkers G.T., Capel P.J., et al. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun 63 1 (1995) 73-81
72. van der Pol W.L., Huizinga T.W., Vidarsson G., van der Linden M.W., Jansen M.D., Keijsers V., et al. Relevance of Fcγ receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 184 12 (2001) 1548-1555
73. Bredius R.G., Derkx B.H., Fijen C.A., de Wit T.P., de Haas M., Weening R.S., et al. Fcγ receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis 170 4 (1994) 848-853
74. Platonov A.E., Shipulin G.A., Vershinina I.V., Dankert J., van de Winkel J.G., and Kuijper E.J. Association of human Fcγ RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis 27 4 (1998) 746-750
75. Smith I., Vedeler C., and Halstensen A. FcγRIIa and FcγRIIIb polymorphisms were not associated with meningococcal disease in Western Norway. Epidemiol Infect 130 2 (2003) 193-199
76. Domingo P., Muniz-Diaz E., Baraldes M.A., Arilla M., Barquet N., Pericas R., et al. Relevance of genetically determined host factors to the prognosis of meningococcal disease. Eur J Clin Microbiol Infect Dis 23 8 (2004) 634-637
77. Domingo P., Muniz-Diaz E., Baraldes M.A., Arilla M., Barquet N., Pericas R., et al. Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. Am J Med 112 1 (2002) 19-25
78. Platonov A.E., Kuijper E.J., Vershinina I.V., Shipulin G.A., Westerdaal N., Fijen C.A., et al. Meningococcal disease and polymorphism of FcγRIIa (CD32) in late complement component-deficient individuals. Clin Exp Immunol 111 1 (1998) 97-101
79. Fijen C.A., Bredius R.G., Kuijper E.J., Out T.A., De Haas M., De Wit A.P., et al. The role of Fcgamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals. Clin Exp Immunol 120 2 (2000) 338-345
80. Powars D., Larsen R., Johnson J., Hulbert T., Sun T., Patch M.J., et al. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis 17 2 (1993) 254-261
81. Faust S.N., Heyderman R.S., and Levin M. Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C. Crit Care Med 29 7 Suppl. (2001) S62-S67 [discussion S7-8]
82. Brandtzaeg P., Sandset P.M., Joo G.B., Ovstebo R., Abildgaard U., and Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 55 4 (1989) 459-470
83. Oragui E.E., Nadel S., Kyd P., and Levin M. Increased excretion of urinary glycosaminoglycans in meningococcal septicemia and their relationship to proteinuria. Crit Care Med 28 8 (2000) 3002-3008
84. Heyderman R.S., Klein N.J., Shennan G.I., and Levin M. Deficiency of prostacyclin production in meningococcal shock. Arch Dis Child 66 11 (1991) 1296-1299
85. Heyderman R.S., Klein N.J., Daramola O.A., Hammerschmidt S., Frosch M., Robertson B.D., et al. Induction of human endothelial tissue factor expression by Neisseria meningitidis: the influence of bacterial killing and adherence to the endothelium. Microb Pathog 22 5 (1997) 265-274
86. Eling M., Stephens A.C., Oragui E.E., Rivers R.P., and Levin M. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease. Thromb Haemost 85 2 (2001) 240-244
87. Faust S.N., Levin M., Harrison O.B., Goldin R.D., Lockhart M.S., Kondaveeti S., et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345 6 (2001) 408-416
88. Brandtzaeg P., Joo G.B., Brusletto B., and Kierulf P. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 57 2 (1990) 271-278
89. Rosendaal F.R., Koster T., Vandenbroucke J.P., and Reitsma P.H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85 6 (1995) 1504-1508
90. Sackesen C., Secmeer G., Gurgey A., Kanra G., Ecevit Z., Ceyhan M., et al. Homozygous Factor V Leiden mutation in a child with meningococcal purpura fulminans. Pediatr Infect Dis J 17 1 (1998) 87
91. Kondaveeti S., Hibberd M.L., Booy R., Nadel S., and Levin M. Effect of the Factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J 18 10 (1999) 893-896
92. Kondaveeti S., Hibberd M.L., and Levin M. The insertion/deletion polymorphism in the t-PA gene does not significantly affect outcome of meningococcal disease. Thromb Haemost 82 1 (1999) 161-162
93. Haralambous E., Hibberd M.L., Hermans P.W., Ninis N., Nadel S., and Levin M. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit Care Med 31 12 (2003) 2788-2793
94. Westendorp R.G., Hottenga J.J., and Slagboom P.E. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 354 9178 (1999) 561-563
95. Geishofer G., Binder A., Muller M., Zohrer B., Resch B., Muller W., et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr 164 8 (2005) 486-490
96. Binder A., Endler G., Muller M., Mannhalter C., and Zenz W. 4G4G genotype of the plasminogen activator inhibitor-1 promoter polymorphism associates with disseminated intravascular coagulation in children with systemic meningococcemia. J Thromb Haemost 5 10 (2007) 2049-2054
97. Hermans P.W., Hibberd M.L., Booy R., Daramola O., Hazelzet J.A., de Groot R., et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Lancet 354 9178 (1999) 556-560
98. Yuksel M., Okajima K., Uchiba M., Horiuchi S., and Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 88 2 (2002) 267-273
99. Spek C.A., Greengard J.S., Griffin J.H., Bertina R.M., and Reitsma P.H. Two mutations in the promoter region of the human protein C gene both cause type I protein C deficiency by disruption of two HNF-3 binding sites. J Biol Chem 270 41 (1995) 24216-24221
100. Binder A., Endler G., Rieger S., Geishofer G., Resch B., Mannhalter C., et al. Protein C promoter polymorphisms associate with sepsis in children with systemic meningococcemia. Hum Genet 122 2 (2007) 183-190
101. Schneider M., Boffa M., Stewart R., Rahman M., Koschinsky M., and Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 277 2 (2002) 1021-1030
102. Kremer Hovinga J.A., Franco R.F., Zago M.A., Ten Cate H., Westendorp R.G., and Reitsma P.H. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease. J Thromb Haemost 2 1 (2004) 54-57
103. Emonts M., de Bruijne E.L., Guimaraes A.H., Declerck P.J., Leebeek F.W., de Maat M.P., et al. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J Thromb Haemost 6 2 (2008) 268-276
104. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., and Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 169 1 (1989) 333-338
105. Newport M.J., Huxley C.M., Huston S., Hawrylowicz C.M., Oostra B.A., Williamson R., et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 335 26 (1996) 1941-1949
106. Levin M., Newport M.J., D'Souza S., Kalabalikis P., Brown I.N., Lenicker H.M., et al. Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene?. Lancet 345 8942 (1995) 79-83
107. Blackwell J.M. The macrophage resistance gene Lsh/Ity/Bcg. Res Immunol 140 8 (1989) 767-769
108. Vidal S.M., Malo D., Vogan K., Skamene E., and Gros P. Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. Cell 73 3 (1993) 469-485
109. Barton C.H., Whitehead S.H., and Blackwell J.M. Nramp transfection transfers Ity/Lsh/Bcg-related pleiotropic effects on macrophage activation: influence on oxidative burst and nitric oxide pathways. Mol Med 1 3 (1995) 267-279
110. Shaw M.A., Clayton D., Atkinson S.E., Williams H., Miller N., Sibthorpe D., et al. Linkage of rheumatoid arthritis to the candidate gene NRAMP1 on 2q35. J Med Genet 33 8 (1996) 672-677
111. Westendorp R.G., Langermans J.A., Huizinga T.W., Elouali A.H., Verweij C.L., Boomsma D.I., et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349 9046 (1997) 170-173
112. Nadel S., Newport M.J., Booy R., and Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 174 4 (1996) 878-880
113. Booy R., Nadel S., Hibberd M., Levin M., and Newport M.J. Genetic influence on cytokine production in meningococcal disease. Lancet 349 9059 (1997) 1176
114. Balding J., Healy C.M., Livingstone W.J., White B., Mynett-Johnson L., Cafferkey M., et al. Genomic polymorphic profiles in an Irish population with meningococcaemia: is it possible to predict severity and outcome of disease?. Genes Immun 4 8 (2003) 533-540
115. Read R.C., Camp N.J., di Giovine F.S., Borrow R., Kaczmarski E.B., Chaudhary A.G., et al. An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. J Infect Dis 182 5 (2000) 1557-1560
116. van Deuren M., van der Ven-Jongekrijg J., Vannier E., van Dalen R., Pesman G., Bartelink A.K., et al. The pattern of interleukin-1β (IL-1β) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections. Blood 90 3 (1997) 1101-1108
117. Read R.C., Cannings C., Naylor S.C., Timms J.M., Maheswaran R., Borrow R., et al. Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. Ann Intern Med 138 7 (2003) 534-541
118. Endler G., Marculescu R., Starkl P., Binder A., Geishofer G., Muller M., et al. Polymorphisms in the interleukin-1 gene cluster in children and young adults with systemic meningococcemia. Clin Chem 52 3 (2006) 511-514
119. Carrol E.D., Mobbs K.J., Thomson A.P., and Hart C.A. Variable number tandem repeat polymorphism of the interleukin-1 receptor antagonist gene in meningococcal disease. Clin Infect Dis 35 4 (2002) 495-497
120. Kornelisse R.F., Hazelzet J.A., Hop W.C., Spanjaard L., Suur M.H., van der Voort E., et al. Meningococcal septic shock in children: clinical and laboratory features, outcome, and development of a prognostic score. Clin Infect Dis 25 3 (1997) 640-646
121. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., and de Vries J.E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174 5 (1991) 1209-1220
122. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., and O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 147 11 (1991) 3815-3822
123. Davila S., and Hibberd M.L. Genome-wide association studies are coming for human infectious diseases. Genome Med 1 2 (2009) 19